PEPN2113: A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy
Protocol #: 22-1539
Location: Childrens Hospital Colorado
|
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Protocol #: 22-1050
Location: CTRC Inpatient, University of Colorado Hospital
|
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)
Protocol #: 21-4798
Location: Childrens Hospital Colorado
|
Do decreased dietary fat and increased fiber reduce recurrence of Clostridioides difficile infection in oncology patients?
Protocol #: 21-2851
Location: Childrens Hospital Colorado, University of Colorado Hospital
|
A PHASE 1 OPEN-LABEL STUDY OF KPT-9274 IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
Protocol #: 20-2350
Location: Lone Tree Medical Center, University of Colorado Hospital
|
CC-486 and Venetoclax for Acute Myeloid Leukemia
Protocol #: 20-1319
Location: Lone Tree Medical Center, University of Colorado Hospital
|
Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy, Followed by Transplantation
Protocol #: 20-1442
Location: Childrens Hospital Colorado
|
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ? Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients (IO-202-CL-001)
Protocol #: 20-1388
Location: Outpatient CTRC, Pathology - SOM, University of Colorado Hospital
|
ADVL1823: Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Protocol #: 19-2469
Location: Childrens Hospital Colorado
|
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol #: 19-2631
Location: Childrens Hospital Colorado
|
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS,
PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION
CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS
AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
Protocol #: 19-2157
Location: Childrens Hospital Colorado
|
COG AAML18P1 - Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Protocol #: 19-1839
Location: Childrens Hospital Colorado
|
Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia (DF/HCC Protocol#: 18-328)
Protocol #: 19-0551
Location: Childrens Hospital Colorado
|
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (aged 18-59) with Acute Myeloid Leukemia
Protocol #: 18-0709
Location: University of Colorado Hospital
|
COG AALL1631 - International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Protocol #: 17-2213
Location: Childrens Hospital Colorado
|
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Protocol #: 17-1086
Location: Childrens Hospital Colorado
|
APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Protocol #: 22-0828
Location: Childrens Hospital Colorado
|
Identification of New Therapeutic Targets in Down Syndrome Acute Lymphoblastic Leukemia
Protocol #: 16-1457
Location: Childrens Hospital Colorado
|
Neurocognitive Function in the Pediatric Hematology Oncology Population
Protocol #: 20-2765
Location: Childrens Hospital Colorado
|
Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial
Protocol #: 20-2525
Location: Childrens Hospital Colorado
|
Paired Germline/Tumor Genetic Testing Outcomes
Protocol #: 20-2287
Location: Childrens Hospital Colorado, Childrens Hospital Colorado at Memorial
|
AAML1831 - A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Protocol #: 20-1864
Location: Childrens Hospital Colorado
|
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Protocol #: 20-0680
Location: Childrens Hospital Colorado
|
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Protocol #: 19-2405
Location: Childrens Hospital Colorado
|
COG AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Protocol #: 19-1634
Location: Childrens Hospital Colorado
|
Laboratory-Based Investigations of Primary Leukemia and Myelodysplastic Syndrome Samples from the University of Colorado's Hematology Tissue Bank Protocol
Protocol #: 19-1498
Location: University of Colorado Hospital
|
Total Joint Arthroplasty in a Pediatric Population
Involves two surveys for approximately 10 mintues...
Protocol #: 19-0306
Location: Childrens Hospital Colorado
|
PHASE 1/2 DOSE ESCALATION AND PRELIMINARY EFFICACY OF CD19 DIRECTED CAR T CELLS GENERATED USING THE MILTENYI CLINIMACS PRODIGY SYSTEM (UCD19 CART) IN PEDIATRIC PATIENTS WITH REPLASED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL)
Protocol #: 18-2424
Location: Childrens Hospital Colorado
|
A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies (M13-833)
Protocol #: 17-0564
Location: Childrens Hospital Colorado
|
Home or away from home: comparing clinical outcomes relevant to the care of pediatric acute myeloid leukemia during periods of neutropenia (Aim 1)
Protocol #: 17-0791
Location: Childrens Hospital Colorado
|
CRIZOTINIB (XALKORI) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERATION BUT WHO ARE UNABLE TO SWALLOW CRIZOTINIB CAPSULES
Protocol #: 16-2544
Location: Childrens Hospital Colorado
|
APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol #: 15-2012
Location: Childrens Hospital Colorado
|
A PHASE II OPEN-LABEL STUDY OF UM171-EXPANDED CORD BLOOD TRANSPLANTATION IN PATIENTS WITH HIGH AND VERY HIGH-RISK ACUTE LEUKEMIA/MYELODYSPLASIA.
Protocol #: 20-3031
Location: University of Colorado Hospital
|
AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
The overall goals of this study are to:
- Find out what effects, good and/or bad, enasidenib has on people with your AML cancer and IDH2 mutation.
- To learn more about the side effects of enasidenib
The study of enasidenib in children and young adults with AML is investigational. T...
Protocol #: 20-3065
Location: Childrens Hospital Colorado
|
A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults with High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial)
Protocol #: 21-2662
Location: Childrens Hospital Colorado
|
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
Protocol #: 18-1893
Location: Childrens Hospital Colorado
|
